We are live on ! Find out more
TAK icon

Takeda Pharmaceutical
TAK

317 hedge funds and large institutions have $2.45B invested in Takeda Pharmaceutical in 2019 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 101 increasing their positions, 98 reducing their positions, and 61 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 98

0.14% less ownership

Funds ownership: 9.2% → 9.06% (-0.14%)

4% less call options, than puts

Call options by funds: $78.2M | Put options by funds: $81.2M

4% less capital invested

Capital invested by funds: $2.57B → $2.45B (-$114M)

9% less funds holding

Funds holding: 347 → 317 (-30)

29% less funds holding in top 10

Funds holding in top 10: 7 → 5 (-2)

46% less first-time investments, than exits

New positions opened: 33 | Existing positions closed: 61

Holders
317
Holders Change
-30
Holders Change %
-8.65%
% of All Funds
6.95%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.11%
New
33
Increased
101
Reduced
98
Closed
61
Calls
$78.2M
Puts
$81.2M
Net Calls
-$3.01M
Net Calls Change
-$19.4M

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$26.6M
2
GC
GMT Capital
Georgia
+$20.4M
3
AC
Adelphi Capital
United Kingdom
+$18.3M
4
GCM
Glenview Capital Management
New York
+$17.5M
5
Renaissance Technologies
Renaissance Technologies
New York
+$16.1M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$36.4M
2
LP
LMR Partners
United Kingdom
-$35.1M
3
NMC
Nine Masts Capital
Hong Kong
-$26.1M
4
MC
Maverick Capital
Texas
-$15.9M
5
Morgan Stanley
Morgan Stanley
New York
-$15.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
UCFA
326
United Capital Financial Advisors
Texas
– -$386K -21,800 Closed
NRS
327
Neville Rodie & Shaw
New York
– -$383K -21,609 Closed
NIT
328
NumerixS Investment Technologies
British Columbia, Canada
– -$342K -19,300 Closed
MCIM
329
Meadow Creek Investment Management
Georgia
– -$304K -17,204 Closed
EP
330
Elkfork Partners
Oregon
– -$251K -14,168 Closed
RCM
331
Riverhead Capital Management
Delaware
– -$225K -12,741 Closed
BCM
332
Bienville Capital Management
New York
– -$223K -12,603 Closed
MCM
333
MAI Capital Management
Ohio
– -$212K -11,974 Closed
TCOT
334
Trust Company of Toledo
Ohio
– -$197K -11,179 Closed
GHCM
335
Glen Harbor Capital Management
California
– -$197K -11,132 Closed
AWA
336
Alaska Wealth Advisors
Alaska
– -$223K -10,923 Closed
AIM
337
Axiom Investment Management
New York
– -$190K -10,639 Closed
EWA
338
EP Wealth Advisors
California
– -$187K -10,546 Closed
BF
339
BOK Financial
Oklahoma
– -$183K -10,317 Closed
RHBC
340
R.H. Bluestein & Co
Michigan
– -$178K -10,068 Closed
NA
341
Neuburgh Advisers
California
– -$143K -8,096 Closed
QT
342
Quantbot Technologies
New York
– -$133K -7,521 Closed
VRM
343
Vectors Research Management
New York
– -$68.2K -3,941 -100%
TPWA
344
TRUE Private Wealth Advisors
Oregon
– -$63K -3,573 Closed
RCC
345
Red Cedar Capital
Nebraska
– -$54K -3,054 Closed
FIA
346
FNY Investment Advisers
New York
– -$38K -2,199 -100%
AC
347
Avestar Capital
New York
– -$35K -2,088 Closed
NCM
348
Next Capital Management
New York
– -$36K -2,025 Closed
TRCT
349
Tower Research Capital (TRC)
New York
– -$34K -1,898 Closed
OIA
350
OneDigital Investment Advisors
Kansas
– -$15K -865 Closed
11 12 13
14
15

TAK Hedge Fund Activity: Q3 2019 in Review

317 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q3 2019, worth a combined $2.45B — down 4.4% from $2.57B a quarter earlier.

Sellers outnumbered buyers: 61 funds closed out of TAK and 33 opened new positions — a net loss of 28 holders — while 98 trimmed existing stakes and 101 added.

The largest buyer was Goldman Sachs, adding an estimated $26.6M. The largest seller was Fidelity Investments, cutting an estimated $36.4M.

  • 317 institutional investors held Takeda Pharmaceutical (TAK) as of Q3 2019, down from 347 in Q2 2019.
  • Funds reported $2.45B of Takeda Pharmaceutical stock for Q3 2019, down 4.4% quarter-over-quarter.
  • 33 funds opened new Takeda Pharmaceutical positions in Q3 2019 and 61 closed out, a net change of -28 holders.
  • The largest Takeda Pharmaceutical buyer in Q3 2019 was Goldman Sachs, an estimated $26.6M added.
  • The largest Takeda Pharmaceutical seller in Q3 2019 was Fidelity Investments, an estimated $36.4M sold.

Based on aggregated 13F filings for Q3 2019.